Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Jeffrey Esko

    SchoolUniversity of California, San Diego
    DepartmentCellular and Molecular Medicine
    Address9500 Gilman Drive #0687
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Biography 
      Collapse Awards and Honors
      NIH1999  - 2009MERIT award
      Society for Glycobiology2007Karl Meyer Award
      Uppsala University2010Doctor of Medicine (honoris causa)
      International Glycoconjugate Organization2011IGO award
      American Association for the Advancement of Science2012Elected Fellow
      NIH2013Director's WALS Lecture

      Collapse Overview 

      Collapse Research 
      Collapse Research Activities and Funding
      Enhancement of wound healing and regeneration through heparan sulfate deficiency
      NIH/NIAMS R61AR073031Sep 1, 2017 - Aug 31, 2019
      Role: Principal Investigator
      Protein Glycosylation in the Coagulopathy and Inflammation of Sepsis
      NIH P01HL131474Jul 15, 2016 - Apr 30, 2021
      Role: Co-Investigator
      5th International MHE Research Conference
      NIH/NIAMS R13AR069987Apr 1, 2016 - Mar 31, 2017
      Role: Principal Investigator
      Genome-wide Analysis of Heparan Sulfate using CRISPR/Cas9
      NIH/NCI R21CA199292Jul 1, 2015 - Jun 30, 2017
      Role: Principal Investigator
      Drug Discovery for Multiple Hereditary Exostoses
      NIH/NIAMS R01AR064202Sep 16, 2013 - Aug 31, 2018
      Role: Principal Investigator
      Glycan Modulation of Inflammatory Responses
      NIH P01HL107150Jul 1, 2011 - May 31, 2018
      Role: Co-Investigator
      Structure and Function of 3-O-sulfation in Heparan Sulfate
      NIH/NIGMS R01GM093131May 1, 2010 - Apr 30, 2014
      Role: Principal Investigator
      Gene Discovery and Heparan Sulfate Biogenesis
      NIH/NHLBI R21HL098910Mar 1, 2010 - Dec 31, 2012
      Role: Principal Investigator
      Shared Instrumentation Grant: LTQ Linear Ion Trap Mass Spectrometer
      NIH/NCRR S10RR025507May 1, 2009 - Apr 30, 2010
      Role: Principal Investigator
      Altered endothelial heparan sulfate causes diaphragmatic hernias resembling CDH
      NIH/NICHD R21HD052920May 1, 2006 - Apr 30, 2009
      Role: Principal Investigator
      Glycoside Inhibitors of Tumor Metastasis
      NIH/NCI R01CA112278Feb 9, 2005 - Jun 30, 2010
      Role: Principal Investigator
      Heparan Sulfate--a Novel Target for Cancer Therapeutics
      NIH/NCI U01CA091290Jun 1, 2001 - May 31, 2006
      Role: Principal Investigator
      NIH/NIAMS R13AR045230Jul 1, 1998 - Jun 30, 1999
      Role: Principal Investigator
      Genetic Modulation of Blood and Vascular Glycosylation
      NIH/NHLBI P01HL057345Sep 30, 1997 - Dec 31, 2013
      Role: Co-Investigator
      Comprehensive Biology: Exploiting the Yeast Genome
      NIH P41RR011823Sep 30, 1996 - Jun 30, 2016
      Role: Co-Investigator
      NIH/NCI R01CA046462Apr 20, 1990 - Jun 30, 2002
      Role: Principal Investigator
      Genetic analysis of proteoglycan-mediated lipoprotein clearance
      NIH/NIGMS R01GM033063Jul 1, 1983 - Apr 30, 2020
      Role: Principal Investigator
      NIH/NIGMS R37GM033063Jul 1, 1983 - Nov 30, 2010
      Role: Principal Investigator
      NIH/NHLBI P50HL023584Dec 1, 1978 - Nov 30, 2003
      Role: Co-Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Ihse E, Yamakado H, van Wijk XM, Lawrence R, Esko J, Masliah E. Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci Rep. 2017 Aug 21; 7(1):9008. PMID: 28827536.
        View in: PubMed
      2. Weiss RJ, Esko J, Tor Y. Targeting heparin and heparan sulfate protein interactions. Org Biomol Chem. 2017 Jul 21; 15(27):5656-5668. PMID: 28653068.
        View in: PubMed
      3. Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko J. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016 Aug 01; 126(8):2855-66. PMID: 27400128; PMCID: PMC4966320 [Available on 11/01/16].
      4. Dwyer CA, Esko J. Glycan susceptibility factors in autism spectrum disorders. Mol Aspects Med. 2016 Oct; 51:104-14. PMID: 27418189.
        View in: PubMed
      5. Hamill KM, McCoy LS, Wexselblatt E, Esko J, Tor Y. Polymyxins Facilitate Entry into Mammalian Cells. Chem Sci. 2016 Aug 01; 7(8):5059-5068. PMID: 28044098.
        View in: PubMed
      6. Thacker BE, Seamen E, Lawrence R, Parker MW, Xu Y, Liu J, Vander Kooi CW, Esko J. Expanding the 3-O-Sulfate Proteome--Enhanced Binding of Neuropilin-1 to 3-O-Sulfated Heparan Sulfate Modulates Its Activity. ACS Chem Biol. 2016 Apr 15; 11(4):971-80. PMID: 26731579.
        View in: PubMed
      7. Varki A, Cummings RD, Aebi M, Packer NH, Seeberger PH, Esko J, Stanley P, Hart G, Darvill A, Kinoshita T, Prestegard JJ, Schnaar RL, Freeze HH, Marth JD, Bertozzi CR, Etzler ME, Frank M, Vliegenthart JF, Lütteke T, Perez S, Bolton E, Rudd P, Paulson J, Kanehisa M, Toukach P, Aoki-Kinoshita KF, Dell A, Narimatsu H, York W, Taniguchi N, Kornfeld S. Symbol Nomenclature for Graphical Representations of Glycans. Glycobiology. 2015 Dec; 25(12):1323-4. PMID: 26543186; PMCID: PMC4643639 [Available on 12/01/16].
      8. Weiss RJ, Gordts PL, Le D, Xu D, Esko J, Tor Y. Small molecule antagonists of cell-surface heparan sulfate and heparin-protein interactions. Chem Sci. 2015 Oct 01; 6(10):5984-5993. PMID: 28133533.
        View in: PubMed
      9. Xu D, Olson J, Cole JN, van Wijk XM, Brinkmann V, Zychlinsky A, Nizet V, Esko J, Chang YC. Heparan Sulfate Modulates Neutrophil and Endothelial Function in Antibacterial Innate Immunity. Infect Immun. 2015 Sep; 83(9):3648-56. PMID: 26150541; PMCID: PMC4534644.
      10. Doody KM, Stanford SM, Sacchetti C, Svensson MN, Coles CH, Mitakidis N, Kiosses WB, Bartok B, Fos C, Cory E, Sah RL, Liu-Bryan R, Boyle DL, Arnett HA, Mustelin T, Corr M, Esko J, Tremblay ML, Firestein GS, Aricescu AR, Bottini N. Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy. Sci Transl Med. 2015 May 20; 7(288):288ra76. PMID: 25995222; PMCID: PMC4458332.
      11. Marki A, Esko J, Pries AR, Ley K. Role of the endothelial surface layer in neutrophil recruitment. J Leukoc Biol. 2015 Oct; 98(4):503-15. PMID: 25979432; PMCID: PMC4569049 [Available on 10/01/16].
      12. Wexselblatt E, Esko J, Tor Y. GNeosomes: Highly Lysosomotropic Nanoassemblies for Lysosomal Delivery. ACS Nano. 2015; 9(4):3961-8. PMID: 25831231.
        View in: PubMed
      13. Akizu N, Cantagrel V, Zaki MS, Al-Gazali L, Wang X, Rosti RO, Dikoglu E, Gelot AB, Rosti B, Vaux KK, Scott EM, Silhavy JL, Schroth J, Copeland B, Schaffer AE, Gordts PL, Esko J, Buschman MD, Field SJ, Napolitano G, Abdel-Salam GM, Ozgul RK, Sagiroglu MS, Azam M, Ismail S, Aglan M, Selim L, Mahmoud IG, Abdel-Hadi S, Badawy AE, Sadek AA, Mojahedi F, Kayserili H, Masri A, Bastaki L, Temtamy S, Müller U, Desguerre I, Casanova JL, Dursun A, Gunel M, Gabriel SB, de Lonlay P, Gleeson JG. Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nat Genet. 2015 May; 47(5):528-34. PMID: 25848753; PMCID: PMC4414867.
      14. Gordts PL, Esko J. Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN-ß. Cytokine. 2015 Mar; 72(1):118-9. PMID: 25573804.
        View in: PubMed
      15. Bernelot Moens SJ, Mooij HL, Hassing HC, Kruit JK, Witjes JJ, van de Sande MA, Nederveen AJ, Xu D, Dallinga-Thie GM, Esko J, Stroes ES, Nieuwdorp M. Carriers of loss-of-function mutations in EXT display impaired pancreatic beta-cell reserve due to smaller pancreas volume. PLoS One. 2014; 9(12):e115662. PMID: 25541963; PMCID: PMC4277348.
      16. Gordts PL, Foley EM, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, Nock R, Glass CK, Erbilgin A, Lusis AJ, Witztum JL, Esko J. Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metab. 2014 Nov 04; 20(5):813-26. PMID: 25440058; PMCID: PMC4254584.
      17. Coulson-Thomas VJ, Gesteira TF, Esko J, Kao W. Heparan sulfate regulates hair follicle and sebaceous gland morphogenesis and homeostasis. J Biol Chem. 2014 Sep 05; 289(36):25211-26. PMID: 25053416; PMCID: PMC4155684.
      18. Wexselblatt E, Esko J, Tor Y. On guanidinium and cellular uptake. J Org Chem. 2014 Aug 01; 79(15):6766-74. PMID: 25019333; PMCID: PMC4120969.
      19. Ge XN, Ha SG, Rao A, Greenberg YG, Rushdi MN, Esko J, Rao SP, Sriramarao P. Endothelial and leukocyte heparan sulfates regulate the development of allergen-induced airway remodeling in a mouse model. Glycobiology. 2014 Aug; 24(8):715-27. PMID: 24794009; PMCID: PMC4070979.
      20. Inoue M, Wexselblatt E, Esko J, Tor Y. Macromolecular uptake of alkyl-chain-modified guanidinoglycoside molecular transporters. Chembiochem. 2014 Mar 21; 15(5):676-80. PMID: 24677320; PMCID: PMC4216228.
      21. Xu D, Esko J. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem. 2014; 83:129-57. PMID: 24606135.
        View in: PubMed
      22. Zhang B, Xiao W, Qiu H, Zhang F, Moniz HA, Jaworski A, Condac E, Gutierrez-Sanchez G, Heiss C, Clugston RD, Azadi P, Greer JJ, Bergmann C, Moremen KW, Li D, Linhardt RJ, Esko J, Wang L. Heparan sulfate deficiency disrupts developmental angiogenesis and causes congenital diaphragmatic hernia. J Clin Invest. 2014 Jan; 124(1):209-21. PMID: 24355925; PMCID: PMC3871243.
      23. Thacker BE, Xu D, Lawrence R, Esko J. Heparan sulfate 3-O-sulfation: a rare modification in search of a function. Matrix Biol. 2014 Apr; 35:60-72. PMID: 24361527; PMCID: PMC4039620.
      24. Lawrence R, Brown JR, Lorey F, Dickson PI, Crawford BE, Esko J. Glycan-based biomarkers for mucopolysaccharidoses. Mol Genet Metab. 2014 Feb; 111(2):73-83. PMID: 23958290; PMCID: PMC3769472.
      25. Foley EM, Gordts PLSM, Stanford KI, Gonzales JC, Lawrence R, Stoddard N, Esko J. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol. 2013 Sep; 33(9):2065-74. PMID: 23846497; PMCID: PMC3821931.
      26. Xu D, Young JH, Krahn JM, Song D, Corbett KD, Chazin WJ, Pedersen LC, Esko J. Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol. 2013 Jul 19; 8(7):1611-20. PMID: 23679870; PMCID: PMC3806902.
      27. Gonzales JC, Gordts PL, Foley EM, Esko J. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest. 2013 Jun; 123(6):2742-51. PMID: 23676495; PMCID: PMC3668842.
      28. Inoue M, Tong W, Esko J, Tor Y. Aggregation-mediated macromolecular uptake by a molecular transporter. ACS Chem Biol. 2013 Jul 19; 8(7):1383-8. PMID: 23621420; PMCID: PMC3773245.
      29. Lawrence R, Brown JR, Lorey F, Dickson PI, Crawford BE, Esko J. WITHDRAWN: Glycan-based biomarkers for mucopolysaccharidoses. Dis Markers. 2013 Feb 08. PMID: 23396297.
        View in: PubMed
      30. Bush KT, Crawford BE, Garner OB, Nigam KB, Esko J, Nigam SK. N-sulfation of heparan sulfate regulates early branching events in the developing mammary gland. J Biol Chem. 2012 Dec 07; 287(50):42064-70. PMID: 23060443; PMCID: PMC3516752.
      31. Axelsson J, Xu D, Kang BN, Nussbacher JK, Handel TM, Ley K, Sriramarao P, Esko J. Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood. 2012 Aug 23; 120(8):1742-51. PMID: 22791291; PMCID: PMC3429312.
      32. Bergfeld AK, Pearce OM, Diaz SL, Lawrence R, Vocadlo DJ, Choudhury B, Esko J, Varki A. Metabolism of vertebrate amino sugars with N-glycolyl groups: incorporation of N-glycolylhexosamines into mammalian glycans by feeding N-glycolylgalactosamine. J Biol Chem. 2012 Aug 17; 287(34):28898-916. PMID: 22692203; PMCID: PMC3436526.
      33. Le Jan S, Hayashi M, Kasza Z, Eriksson I, Bishop JR, Weibrecht I, Heldin J, Holmborn K, Jakobsson L, Söderberg O, Spillmann D, Esko J, Claesson-Welsh L, Kjellén L, Kreuger J. Functional overlap between chondroitin and heparan sulfate proteoglycans during VEGF-induced sprouting angiogenesis. Arterioscler Thromb Vasc Biol. 2012 May; 32(5):1255-63. PMID: 22345168; PMCID: PMC3331918.
      34. Lawrence R, Brown JR, Al-Mafraji K, Lamanna WC, Beitel JR, Boons GJ, Esko J, Crawford BE. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol. 2012 Jan 08; 8(2):197-204. PMID: 22231271; PMCID: PMC3262053.
      35. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, Esko J. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology. 2012 Jan; 55(1):277-86. PMID: 21898481; PMCID: PMC3245353.
      36. Xu D, Young J, Song D, Esko J. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J Biol Chem. 2011 Dec 02; 286(48):41736-44. PMID: 21990362; PMCID: PMC3308882.
      37. Zhao W, Garron ML, Yang B, Xiao Z, Esko J, Cygler M, Linhardt RJ. Asparagine 405 of heparin lyase II prevents the cleavage of glycosidic linkages proximate to a 3-O-sulfoglucosamine residue. FEBS Lett. 2011 Aug 04; 585(15):2461-6. PMID: 21741976; PMCID: PMC3338322.
      38. Sarrazin S, Lamanna WC, Esko J. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011 Jul 01; 3(7). PMID: 21690215; PMCID: PMC3119907.
      39. Chang YC, Wang Z, Flax LA, Xu D, Esko J, Nizet V, Baron MJ. Glycosaminoglycan binding facilitates entry of a bacterial pathogen into central nervous systems. PLoS Pathog. 2011 Jun; 7(6):e1002082. PMID: 21731486; PMCID: PMC3121876.
      40. Zaiss AK, Lawrence R, Elashoff D, Esko J, Herschman HR. Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate. J Biol Chem. 2011 Jul 15; 286(28):24535-43. PMID: 21596747; PMCID: PMC3137028.
      41. Shah MM, Sakurai H, Gallegos TF, Sweeney DE, Bush KT, Esko J, Nigam SK. Growth factor-dependent branching of the ureteric bud is modulated by selective 6-O sulfation of heparan sulfate. Dev Biol. 2011 Aug 01; 356(1):19-27. PMID: 21600196; PMCID: PMC3130836.
      42. Garner OB, Bush KT, Nigam KB, Yamaguchi Y, Xu D, Esko J, Nigam SK. Stage-dependent regulation of mammary ductal branching by heparan sulfate and HGF-cMet signaling. Dev Biol. 2011 Jul 15; 355(2):394-403. PMID: 21586278; PMCID: PMC3118867.
      43. Zak BM, Schuksz M, Koyama E, Mundy C, Wells DE, Yamaguchi Y, Pacifici M, Esko J. Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones. Bone. 2011 May 01; 48(5):979-87. PMID: 21310272; PMCID: PMC3335264.
      44. Lamanna WC, Lawrence R, Sarrazin S, Esko J. Secondary storage of dermatan sulfate in Sanfilippo disease. J Biol Chem. 2011 Mar 04; 286(9):6955-62. PMID: 21193389; PMCID: PMC3044951.
      45. Bishop JR, Passos-Bueno MR, Fong L, Stanford KI, Gonzales JC, Yeh E, Young SG, Bensadoun A, Witztum JL, Esko J, Moulton KS. Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans. PLoS One. 2010 Nov 10; 5(11):e13919. PMID: 21085708; PMCID: PMC2978080.
      46. Dix AV, Fischer L, Sarrazin S, Redgate CP, Esko J, Tor Y. Cooperative, heparan sulfate-dependent cellular uptake of dimeric guanidinoglycosides. Chembiochem. 2010 Nov 02; 11(16):2302-10. PMID: 20931643; PMCID: PMC2997625.
      47. Xu D, Fuster MM, Lawrence R, Esko J. Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability. J Biol Chem. 2011 Jan 07; 286(1):737-45. PMID: 20974861; PMCID: PMC3013032.
      48. Crawford BE, Garner OB, Bishop JR, Zhang DY, Bush KT, Nigam SK, Esko J. Loss of the heparan sulfate sulfotransferase, Ndst1, in mammary epithelial cells selectively blocks lobuloalveolar development in mice. PLoS One. 2010 May 18; 5(5):e10691. PMID: 20502530; PMCID: PMC2872662.
      49. Sarrazin S, Wilson B, Sly WS, Tor Y, Esko J. Guanidinylated neomycin mediates heparan sulfate-dependent transport of active enzymes to lysosomes. Mol Ther. 2010 Jul; 18(7):1268-74. PMID: 20442709; PMCID: PMC2911259.
      50. Bishop JR, Foley E, Lawrence R, Esko J. Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate. J Biol Chem. 2010 May 07; 285(19):14658-62. PMID: 20236939; PMCID: PMC2863227.
      51. Adhikari N, Basi DL, Townsend D, Rusch M, Mariash A, Mullegama S, Watson A, Larson J, Tan S, Lerman B, Esko J, Selleck SB, Hall JL. Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. J Mol Cell Cardiol. 2010 Aug; 49(2):287-93. PMID: 20206635; PMCID: PMC2885463.
      52. Shah MM, Sakurai H, Sweeney DE, Gallegos TF, Bush KT, Esko J, Nigam SK. Hs2st mediated kidney mesenchyme induction regulates early ureteric bud branching. Dev Biol. 2010 Mar 15; 339(2):354-65. PMID: 20059993; PMCID: PMC2834281.
      53. Foley EM, Esko J. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins. Prog Mol Biol Transl Sci. 2010; 93:213-33. PMID: 20807647.
        View in: PubMed
      54. Varki A, Cummings RD, Esko J, Freeze HH, Stanley P, Marth JD, Bertozzi CR, Hart GW, Etzler ME. Symbol nomenclature for glycan representation. Proteomics. 2009 Dec; 9(24):5398-9. PMID: 19902428; PMCID: PMC2882983.
      55. Stanford KI, Wang L, Castagnola J, Song D, Bishop JR, Brown JR, Lawrence R, Bai X, Habuchi H, Tanaka M, Cardoso WV, Kimata K, Esko J. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem. 2010 Jan 01; 285(1):286-94. PMID: 19889634; PMCID: PMC2804175.
      56. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko J. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009 Nov; 119(11):3236-45. PMID: 19805913.
        View in: PubMed
      57. Xu D, Esko J. A Golgi-on-a-chip for glycan synthesis. Nat Chem Biol. 2009 Sep; 5(9):612-3. PMID: 19690535.
        View in: PubMed
      58. Brown JR, Yang F, Sinha A, Ramakrishnan B, Tor Y, Qasba PK, Esko J. Deoxygenated disaccharide analogs as specific inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated tumor metastasis. J Biol Chem. 2009 Feb 20; 284(8):4952-9. PMID: 19106107; PMCID: PMC2643505.
      59. Meissen JK, Sweeney MD, Girardi M, Lawrence R, Esko J, Leary JA. Differentiation of 3-O-sulfated heparin disaccharide isomers: identification of structural aspects of the heparin CCL2 binding motif. J Am Soc Mass Spectrom. 2009 Apr; 20(4):652-7. PMID: 19185514; PMCID: PMC2758813.
      60. Bakker H, Oka T, Ashikov A, Yadav A, Berger M, Rana NA, Bai X, Jigami Y, Haltiwanger RS, Esko J, Gerardy-Schahn R. Functional UDP-xylose transport across the endoplasmic reticulum/Golgi membrane in a Chinese hamster ovary cell mutant defective in UDP-xylose Synthase. J Biol Chem. 2009 Jan 23; 284(4):2576-83. PMID: 19028698; PMCID: PMC2629108.
      61. Weinstein MM, Yin L, Beigneux AP, Davies BS, Gin P, Estrada K, Melford K, Bishop JR, Esko J, Dallinga-Thie GM, Fong LG, Bensadoun A, Young SG. Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem. 2008 Dec 12; 283(50):34511-8. PMID: 18845532; PMCID: PMC2596386.
      62. Lawrence R, Olson SK, Steele RE, Wang L, Warrior R, Cummings RD, Esko J. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem. 2008 Nov 28; 283(48):33674-84. PMID: 18818196; PMCID: PMC2586254.
      63. Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, Glass CA, Wang L, Tor Y, Esko J. Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A. 2008 Sep 02; 105(35):13075-80. PMID: 18725627; PMCID: PMC2529023.
      64. Varki AP, Baum LG, Bellis SL, Cummings RD, Esko J, Hart GW, Linhardt RJ, Lowe JB, McEver RP, Srivastava A, Sarkar R. Working group report: the roles of glycans in hemostasis, inflammation and vascular biology. Glycobiology. 2008 Oct; 18(10):747-9. PMID: 18621991.
        View in: PubMed
      65. Bishop JR, Stanford KI, Esko J. Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol. 2008 Jun; 19(3):307-13. PMID: 18460924.
        View in: PubMed
      66. Garner OB, Yamaguchi Y, Esko J, Videm V. Small changes in lymphocyte development and activation in mice through tissue-specific alteration of heparan sulphate. Immunology. 2008 Nov; 125(3):420-9. PMID: 18479348; PMCID: PMC2669145.
      67. Lawrence R, Lu H, Rosenberg RD, Esko J, Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods. 2008 Apr; 5(4):291-2. PMID: 18376390.
        View in: PubMed
      68. Bode L, Salvestrini C, Park PW, Li JP, Esko J, Yamaguchi Y, Murch S, Freeze HH. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest. 2008 Jan; 118(1):229-38. PMID: 18064305; PMCID: PMC2117765.
      69. Coppi A, Tewari R, Bishop JR, Bennett BL, Lawrence R, Esko J, Billker O, Sinnis P. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe. 2007 Nov 15; 2(5):316-27. PMID: 18005753; PMCID: PMC2117360.
      70. Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL, Sriramarao P, Esko J. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol. 2007 May 07; 177(3):539-49. PMID: 17470635; PMCID: PMC2064806.
      71. Bishop JR, Schuksz M, Esko J. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007 Apr 26; 446(7139):1030-7. PMID: 17460664.
        View in: PubMed
      72. Johnson CE, Crawford BE, Stavridis M, Ten Dam G, Wat AL, Rushton G, Ward CM, Wilson V, van Kuppevelt TH, Esko J, Smith A, Gallagher JT, Merry CL. Essential alterations of heparan sulfate during the differentiation of embryonic stem cells to Sox1-enhanced green fluorescent protein-expressing neural progenitor cells. Stem Cells. 2007 Aug; 25(8):1913-23. PMID: 17464092.
        View in: PubMed
      73. Elson-Schwab L, Garner OB, Schuksz M, Crawford BE, Esko J, Tor Y. Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway. J Biol Chem. 2007 May 04; 282(18):13585-91. PMID: 17311923.
        View in: PubMed
      74. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko J. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007 Jan; 117(1):153-64. PMID: 17200715; PMCID: PMC1716206.
      75. Pönighaus C, Ambrosius M, Casanova JC, Prante C, Kuhn J, Esko J, Kleesiek K, Götting C. Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. J Biol Chem. 2007 Feb 23; 282(8):5201-6. PMID: 17189265.
        View in: PubMed
      76. Olson SK, Bishop JR, Yates JR, Oegema K, Esko J. Identification of novel chondroitin proteoglycans in Caenorhabditis elegans: embryonic cell division depends on CPG-1 and CPG-2. J Cell Biol. 2006 Jun 19; 173(6):985-94. PMID: 16785326; PMCID: PMC2063922.
      77. Brown JR, Nishimura Y, Esko J. Synthesis and biological evaluation of gem-diamine 1-N-iminosugars related to L-iduronic acid as inhibitors of heparan sulfate 2-O-sulfotransferase. Bioorg Med Chem Lett. 2006 Feb; 16(3):532-6. PMID: 16275065.
        View in: PubMed
      78. Stickens D, Zak BM, Rougier N, Esko J, Werb Z. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development. 2005 Nov; 132(22):5055-68. PMID: 16236767; PMCID: PMC2767329.
      79. Comelli EM, Head SR, Gilmartin T, Whisenant T, Haslam SM, North SJ, Wong NK, Kudo T, Narimatsu H, Esko J, Drickamer K, Dell A, Paulson JC. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology. 2006 Feb; 16(2):117-31. PMID: 16237199.
        View in: PubMed
      80. Bishop JR, Crawford BE, Esko J. Cell surface heparan sulfate promotes replication of Toxoplasma gondii. Infect Immun. 2005 Sep; 73(9):5395-401. PMID: 16113255; PMCID: PMC1231081.
      81. Fuster MM, Esko J. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005 Jul; 5(7):526-42. PMID: 16069816.
        View in: PubMed
      82. Bishop JR, Esko J. The elusive role of heparan sulfate in Toxoplasma gondii infection. Mol Biochem Parasitol. 2005 Feb; 139(2):267-9. PMID: 15664661.
        View in: PubMed
      83. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004 Nov; 6(5):485-95. PMID: 15542432.
        View in: PubMed
      84. Steer DL, Shah MM, Bush KT, Stuart RO, Sampogna RV, Meyer TN, Schwesinger C, Bai X, Esko J, Nigam SK. Regulation of ureteric bud branching morphogenesis by sulfated proteoglycans in the developing kidney. Dev Biol. 2004 Aug 15; 272(2):310-27. PMID: 15282150.
        View in: PubMed
      85. Griffitts JS, Huffman DL, Whitacre JL, Barrows BD, Marroquin LD, Müller R, Brown JR, Hennet T, Esko J, Aroian RV. Resistance to a bacterial toxin is mediated by removal of a conserved glycosylation pathway required for toxin-host interactions. J Biol Chem. 2003 Nov 14; 278(46):45594-602. PMID: 12944392.
        View in: PubMed
      86. Fuster MM, Brown JR, Wang L, Esko J. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res. 2003 Jun 01; 63(11):2775-81. PMID: 12782582.
        View in: PubMed
      87. Hwang HY, Olson SK, Esko J, Horvitz HR. Caenorhabditis elegans early embryogenesis and vulval morphogenesis require chondroitin biosynthesis. Nature. 2003 May 22; 423(6938):439-43. PMID: 12761549.
        View in: PubMed
      88. Hwang HY, Olson SK, Brown JR, Esko J, Horvitz HR. The Caenorhabditis elegans genes sqv-2 and sqv-6, which are required for vulval morphogenesis, encode glycosaminoglycan galactosyltransferase II and xylosyltransferase. J Biol Chem. 2003 Apr 04; 278(14):11735-8. PMID: 12584198.
        View in: PubMed
      89. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko J, Kjellén L. Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim Biophys Acta. 2002 Dec 19; 1573(3):209-15. PMID: 12417402.
        View in: PubMed
      90. Mertsching E, Wurster AL, Katayama C, Esko J, Ramsdell F, Marth JD, Hedrick SM. A mouse strain defective for alphabeta versus gammadelta T cell lineage commitment. Int Immunol. 2002 Sep; 14(9):1039-53. PMID: 12202401.
        View in: PubMed
      91. Wang L, Brown JR, Varki A, Esko J. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002 Jul; 110(1):127-36. PMID: 12093896; PMCID: PMC151027.
      92. Grobe K, Esko J. Regulated translation of heparan sulfate N-acetylglucosamine N-deacetylase/n-sulfotransferase isozymes by structured 5'-untranslated regions and internal ribosome entry sites. J Biol Chem. 2002 Aug 23; 277(34):30699-706. PMID: 12070138.
        View in: PubMed
      93. Guibinga GH, Miyanohara A, Esko J, Friedmann T. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther. 2002 May; 5(5 Pt 1):538-46. PMID: 11991744.
        View in: PubMed
      94. Belting M, Borsig L, Fuster MM, Brown JR, Persson L, Fransson LA, Esko J. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):371-6. PMID: 11752393; PMCID: PMC117567.
      95. Esko J, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002; 71:435-71. PMID: 12045103.
        View in: PubMed
      96. Esko J, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest. 2001 Jul; 108(2):169-73. PMID: 11457867; PMCID: PMC203033.
      97. Esko J, Zhang L. Influence of core protein sequence on glycosaminoglycan assembly. Curr Opin Struct Biol. 1996 Oct; 6(5):663-70. PMID: 8913690.
        View in: PubMed
      Jeffrey's Networks
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Similar People
      People who share similar concepts with this person.
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.